Multiple endocrine neoplasia type 1
Updates to Article Attributes
Multiple endocrine neoplasia type I (MEN1)is also, also known as Wermer syndrome, is an autosomal dominant genetic disease that results in proliferative lesions in multiple endocrine organs, particularly the pituitary gland, islet cells of the pancreas and parathyroid glands.
There are other multiple endocrine neoplasia syndromes and these are discussed separately.
Clinical presentation
Primary hyperparathyroidism is one of the commonest presentationspresentation, followed by pancreatic islet cell tumour with associated hypersecretion syndromes; gastrinomas are most common and associate with Zollinger-Ellison syndrome7.
Pathology
The abnormality is related to a tumour suppressor gene located in chromosome 11q13. MEN type I is an autosomal dominant syndrome characterised by1-7:
-
pituitary adenomas
:- prolactinoma (most common)
- 30% of patients
, most frequentlyprolactinomas
-
islet cell tumours of the pancreas
: 50% of patients, and a significant cause of mortality, most oftengastrinomasfollowed- gastrinoma (most common) followed by glucagonoma
- 50-80% of patients
- a significant cause of mortality
-
proliferative parathyroid gland lesions 7
-
parathyroid hyperplasia
: with resulting(most common)-
hyperparathyroidism
seenis seen in 80-95% of patients
-
hyperparathyroidism
- parathyroid adenoma
- parathyroid carcinoma (rare)
-
parathyroid hyperplasia
Handy mnemonics for recalling MEN type I:
- PPP or PiParPanc
Associations
In addition to the aforementioned characteristic lesions involving the pituitary, parathyroid and pancreas, numerous other lesions are encountered with greater frequency in patients with MEN1. These include:
- lipomas
- angiofibromas
-
adrenal cortical lesions
- adrenal adenomas
- adrenocortical hyperplasia
- cortisol-secreting adenomas
- adrenal carcinomas (rare)
- carcinoid tumours
- hepatic focal nodular hyperplasia 5
-
Zollinger-Ellison syndrome6
Treatment and prognosis
Treatment is directed to each individual manifestation. These are therefore discussed separately.
Pancreatic malignancy is the leading cause of mortality in MEN type I.
History and etymology
ItMEN1 was first characterised by P Wermer et al. in 1954 3.
See also
- MEN1 (Wermer syndrome)
-
MEN2
(multiple endocrine adenomatosis)- MEN2a (Sipple syndrome)
- MEN2b (mucosal neuroma syndrome)
- familial medullary thyroid carcinoma
- MEN4
- Carney complex
-<p><strong>Multiple endocrine neoplasia type I (MEN1) </strong>is also known as <strong>Wermer syndrome</strong>.</p><h4>Clinical presentation</h4><p><a href="/articles/primary-hyperparathyroidism">Primary hyperparathyroidism</a> is one of the commonest presentations.</p><h4>Pathology</h4><p>The abnormality is related to a tumour suppressor gene located in chromosome 11q13. MEN type I is an autosomal dominant syndrome characterised by:</p><ul>- +<p><strong>Multiple endocrine neoplasia type I (MEN1)</strong>, also known as <strong>Wermer syndrome</strong>, is an autosomal dominant genetic disease that results in proliferative lesions in multiple endocrine organs, particularly the <a title="Pituitary gland" href="/articles/pituitary-gland">pituitary gland</a>, islet cells of the <a title="Pancreas" href="/articles/pancreas">pancreas</a> and <a title="Parathyroid glands" href="/articles/parathyroid-glands">parathyroid glands</a>. </p><p>There are other <a title="MEN syndromes" href="/articles/multiple-endocrine-neoplasia-syndromes">multiple endocrine neoplasia </a><a title="MEN syndromes" href="/articles/multiple-endocrine-neoplasia-syndromes">syndromes</a> and these are discussed separately. </p><h4>Clinical presentation</h4><p><a href="/articles/primary-hyperparathyroidism">Primary hyperparathyroidism</a> is the commonest presentation, followed by pancreatic islet cell tumour with associated hypersecretion syndromes; <a title="Gastrinomas" href="/articles/gastrinoma">gastrinomas</a> are most common and associate with <a title="Zollinger-Ellison syndrome" href="/articles/zollinger-ellison-syndrome">Zollinger-Ellison syndrome</a> <sup>7</sup>. </p><h4>Pathology</h4><p>The abnormality is related to a tumour suppressor gene located in chromosome 11q13. MEN type I is an autosomal dominant syndrome characterised by <sup>1-7</sup>:</p><ul>
-<a href="/articles/pituitary-adenoma">pituitary adenomas</a>: 30% of patients, most frequently <a href="/articles/prolactinoma">prolactinomas</a>- +<a href="/articles/pituitary-adenoma">pituitary adenomas</a><ul>
- +<li>
- +<a href="/articles/prolactinoma">prolactinoma</a> (most common)</li>
- +<li>30% of patients</li>
- +</ul>
-<a href="/articles/endocrine-tumours-of-the-pancreas">islet cell tumours of the pancreas</a>: 50% of patients, and a significant cause of mortality, most often <a href="/articles/gastrinoma">gastrinomas </a>followed by <a href="/articles/glucagonoma">glucagonoma</a>- +<a href="/articles/endocrine-tumours-of-the-pancreas">islet cell tumours of the pancreas</a><ul>
- +<li>
- +<a href="/articles/gastrinoma">gastrinoma</a> (most common) followed by <a href="/articles/glucagonoma">glucagonoma</a>
- +<li>50-80% of patients</li>
- +<li>a significant cause of mortality</li>
- +</ul>
- +</li>
- +<li>proliferative parathyroid gland lesions <sup>7</sup><ul>
-<a href="/articles/parathyroid-hyperplasia">parathyroid hyperplasia</a>: with resulting <a href="/articles/hyperparathyroidism">hyperparathyroidism</a> seen in 80-95% of patients</li>-</ul><p>Handy mnemonics for recalling MEN type I: </p><ul><li>PPP or PiParPanc</li></ul><h5>Associations</h5><ul>- +<a href="/articles/parathyroid-hyperplasia">parathyroid hyperplasia</a> (most common)<ul><li>
- +<a href="/articles/hyperparathyroidism">hyperparathyroidism</a> is seen in 80-95% of patients</li></ul>
- +</li>
- +<li><a title="Parathyroid adenoma" href="/articles/parathyroid-adenoma">parathyroid adenoma</a></li>
- +<li>
- +<a title="parathyroid carcinoma" href="/articles/parathyroid-carcinoma">parathyroid carcinoma</a> (rare)</li>
- +</ul>
- +</li>
- +</ul><p>Handy mnemonics for recalling MEN type I: </p><ul><li>PPP or PiParPanc</li></ul><h5>Associations</h5><p>In addition to the aforementioned characteristic lesions involving the pituitary, parathyroid and pancreas, numerous other lesions are encountered with greater frequency in patients with MEN1. These include: </p><ul>
-<li>-<a href="/articles/zollinger-ellison-syndrome">Zollinger-Ellison syndrome</a><sup> 6</sup>-</li>-</ul><h4>Treatment and prognosis</h4><p>Pancreatic malignancy is the leading cause of mortality in MEN type I. </p><h4>History and etymology</h4><p>It was first characterised by <strong>P Wermer</strong> et al. in 1954 <sup>3</sup>.</p><h4>See also</h4><ul>- +</ul><h4>Treatment and prognosis</h4><p>Treatment is directed to each individual manifestation. These are therefore discussed separately.</p><p>Pancreatic malignancy is the leading cause of mortality in MEN type I. </p><h4>History and etymology</h4><p>MEN1 was first characterised by <strong>P Wermer</strong> et al. in 1954 <sup>3</sup>.</p><h4>See also</h4><ul>
-<a href="/articles/multiple-endocrine-neoplasia-type-ii-1">MEN2</a> (multiple endocrine adenomatosis)<ul>- +<a href="/articles/multiple-endocrine-neoplasia-type-ii-1">MEN2</a><ul>
References changed:
- 7. Gianani R. The multiple endocrine neoplasia type-1 (MEN-1) syndrome and its effect on the pancreas. (2007) The Journal of clinical endocrinology and metabolism. 92 (3): 811-2. <a href="https://doi.org/10.1210/jc.2007-0104">doi:10.1210/jc.2007-0104</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/17341576">Pubmed</a> <span class="ref_v4"></span>